Trophos Appoints JSB Partners as Global Partnership Advisor
Complete the form below to unlock access to ALL audio articles.
Trophos SA has announced the appointment of JSB Partners, a global life sciences advisor.
JSB Partners has been selected by Trophos to assist the company in executing its business development objectives. These aim to put in place strategic partnerships for Trophos’ advanced clinical development programs:
• Olesoxime, which is presently being tested in a pivotal trial in Spinal Muscular Atrophy (SMA) with results due in the second half of 2013;
• Olesoxime for Multiple Sclerosis (MS) disease progression, with a phase II proof-of-concept trial designed with global MS experts, ready to be initiated leading to results in 2016;
• TRO40303, in an ongoing phase IIa proof-of-concept study in cardiac ischemia-reperfusion injury (IRI), with results due in the first half of 2013
“Trophos has always followed a unique path, forming consortia to work on high medical need orphan or niche indications with no existing treatments,” said Christine Placet, CEO Trophos.
Placet continued, “The expertise of world leading specialists within these conditions has contributed to and enhanced the Trophos pipeline. Both the market potential of our candidates - nearly USD two billion, as well as the patients suffering from terrible orphan diseases and conditions, deserve optimal partnerships to advance therapies and cures for these conditions. This is why we have appointed some of the best advisors to help us.”
“There is considerable market potential for the conditions targeted by the Trophos pipeline,” said Michel Gouy, partner, JSB-Partners. “It is critical to find the right partnerships for continued advancement in treatment for these conditions.”
